**BACKGROUND**

The Vav gene was originally identified on the basis of its oncogenic activation during the course of gene transfer assays. The major translational product of the Vav proto-oncogene has been identified as a protein containing an array of structural motifs. This protein, known as Vav, Vav1 or p95Vav, contains an N-terminal helix-loop-helix domain and a leucine zipper motif similar to that of Myc family proteins that, if deleted, causes oncogenic activation. In addition, Vav contains an SH2 domain, which could indicate its role as a substrate for tyrosine kinases. Expression of Vav is limited exclusively to cells of hematopoietic origin, including those of the erythroid, lymphoid and myeloid lineages. These results suggest that Vav may represent a new type of signal transduction molecule involved in the transduction of tyrosine phosphorylation signaling into transcriptional events.

**CHROMOSOMAL LOCATION**

Genetic locus: VAV1 (human) mapping to 19p13.3.

**SOURCE**

Vav (E-4) is a mouse monoclonal antibody raised against amino acids 110-320 mapping to a central domain of Vav p95 of human origin.

**PRODUCT**

Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Vav (E-4) is available conjugated to agarose (sc-17831 AC), 500 µg/0.25 ml agarose in 1 ml, for IP; to HRP (sc-17831 HRP), 200 µg/ml, for WB, IHC and FCM; to either Alexa Fluor® 680 (sc-17831 AF680) or Alexa Fluor® 790 (sc-17831 AF790), 200 µg/ml, for Near-Infrared (NIR) WB, IF and FCM.

**RECOMMENDED SUPPORT REAGENTS**

To ensure optimal results, the following support reagents are recommended:
1. Western Blotting: use m-IgG κ BP-HRP: sc-516102 or m-IgG κ BP-PE: sc-516148.
2. Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml).

**DATA**

**SELECT PRODUCT CITATIONS**


**STORAGE**

Store at 4°C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.